LEPU Scientech Medical Technology (Shanghai) Co., Ltd. provided consolidated earnings guidance for the year ended December 31, 2023. For the period, the Group is expected to record a net profit attributable to owners of the Company ranging from approximately RMB 140 million to approximately RMB 160 million, as compared with a loss attributable to owners of the Company of RMB 19.8 million for the year ended December 31, 2022. It is estimated that the non-IFRS profit is ranging from approximately RMB 160 million to approximately RMB 180 million as compared with that of approximately RMB 111.1 million for the year ended December 31, 2022.

Based on currently available information, the expected increase in net profit attributable to the Shareholders was mainly due to the followings: the sales volume of the Group's last generation of nitinol occluder products during the Reporting Period increased significantly compared with the year ended December 31, 2022. This growth was driven by the Group's forward-looking strategic mindset in Research and Development (R&D), strong marketing capabilities, effective academic promotion and extensive distributor network, which further increased the sales volume of such products in the market; and in view of the Group's consistent the R&D innovation strategy, the MemoSorb® full- biodegradable polymer-based occluder systems of which the Center for Drug Evaluation of the National Medical Products Administration of the PRC (CDE) registration certificate was obtained in February 2022 and the MemoSorb ® biodegradable patent foramen ovale occluder of which the CDE registration certificate was obtained in September 2023, both being the Group's innovative products, have achieved better sales results during the Reporting Period as compared to the year ended December 31, 2022.